samedan logo
home > pmps > spring 2013 > brave new world
Pharmaceutical Manufacturing and Packing Sourcer

Brave New World

PMPS: What attracted you to the pharmaceutical industry?

Adam Crossno: The challenge and the impact. The industry is driven by regulations that push everyone to ensure the highest quality possible, and I am passionate about delivering that quality and rising to a challenge. From an impact perspective there is nothing greater than helping to change lives, and our work in ensuring the quality and consistency of pharmaceutical transport helps do just that.

Which part of your job do you most enjoy?

Bringing new solutions to market that deliver layers of value, drive new efficiencies and increase the velocity of business. I am fascinated by innovative technology and services that change the way companies operate.

Which part is the most difficult?

Colouring within the lines. We pride ourselves on thinking outside the box, and sometimes it can be challenging to change mindsets and get people looking towards the future. But we never stop trying.

How would you describe your business philosophy?

Be honest and always maintain your integrity. Opportunities will always arise that tempt you to take shortcuts. Stand by your word and never lose the hope that “what’s right is right and what goes around comes around”.

What drives you?

Changing the world. At the end of the day, the legacy you leave behind is the only thing that really matters. If you can honestly say that you have made an impact on the way people live their lives, or on how businesses operate, or even on the way whole industries interact – that’s the real driver.

What have been your proudest moments?

Being involved with delivering the world’s first global, autonomous tracking and monitoring device that is fully approved for use on aircraft – and getting to lead the hugely talented team that conceptualised, invented, patented, delivered and marketed the solution – are among my proudest moments to date.

What keeps you awake at night?

Trying to stay ahead of the curve. Deciding how to prioritise efforts and where to apply resources – ideas for innovation come easy, but delivering them to market is a different story. It takes a unique combination of vision, risk-taking and pragmatic reflection to make the right choices.

What do you think the pharmaceutical industry needs to focus on in 2013?

Looking at the whole picture. Delivering product to a customer involves many moving parts and many partners – opportunities to harvest efficiency exist everywhere, but you don’t see it until you look all around. We help our customers see their options more clearly and, selfishly, I believe the industry needs to exploit these visibility solutions to help them operate more effi ciently, delivering the quality and assurance the marketplace demands.

How do you think the industry will change over the next decade?

Collaboration through technology will become pervasive. All entities, from manufacturing to supply chain to the end customer, will be connected in real time. With nowhere to hide, all players will need to be at the top of their game – if you are unable to demonstrate both quality and performance, you will be found out.

What is the most important lesson you have learnt?

Nothing is ever quick and easy. Absolutely everything worthwhile takes blood, sweat, tears and real effort to achieve success.

What would you like this year to bring?

More business. We are working hard to tell the world about what we have to offer, and the tide is turning for us. We are passionate about delivering value and would like the opportunity to do that on an even larger scale than before.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
Adam Crossno is President and CEO of OnAsset Intelligence Inc. His career has spanned many roles, ranging from Engineering Technician to Vice President, and he has much experience in implementing solutions for a variety of industry sectors. Adam was recently recognised by DHL with a Global Technology Award for the FlightSafe technology he developed.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines

PARIS & OXFORD, England & BOSTON--(BUSINESS WIRE)-- Sanofi and Exscientia announced today a groundbreaking research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia’s end-to-end AI-driven platform utilising actual patient samples. The companies have been working together since 2016 and in 2019, Sanofi in-licensed Exscientia’s novel bispecific small molecule candidate capable of targeting two distinct targets in inflammation and immunology.
More info >>

White Papers

High Potency Drugs – from Molecule to Market

PCI Pharma Services

PCI Pharma Services has invested in state-of-the-art containment equipment and created a ‘Potent Passport’ philosophy to identify the specific handling requirements for any Highly Potent Active Pharmaceutical Ingredients (HPAPI) project. Backed by 30 years’ experience of managing potent molecules, PCI Pharma Services is the logical choice when selecting an outsourcing partner.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement